BNET Industries
Last Fiscal Year Sales:$274.7M
- Public
- US
Dow Jones Description
Provider of Human Antibody-Based Products & Services to Major Health Care Companies
Number of Employees 912
Peer Companies
NAICS Code Research and Development in the Social Sciences and Humanities: 541720
News & Analysis
Filter by
serologicals corp. - All News and Analysis
Celliance Enters Agreement with Novozymes A/S to Develop Animal-Free Recombinant Human Albumin
ATLANTA -- Serologicals Corporation (NASDAQ:SERO), announced today that Celliance Corporation, its wholly-owned subsidiary, has entered into an exclusive agreement with Novozymes A/S to explore the commercialization of Recombinant Human Albumin for use in cell culture media formulations. The agreement commits both companies to an exclusive, long-term supply agreement if specified...
Serologicals' Upstate Group Announces Winner of 2006 Young Cell Signaller Award; Rashu Bhargava Seth Receives Award at the Third Annual Cell Signalling Symposium
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) today announced that Rashu Bhargava Seth, from the University of Texas Southwestern Medical Center at Dallas, has been named the 2006 Young Cell Signaller. She was chosen from among five finalists and more than 86 entries in its Upstate 2006 Young Cell Signaller Award...
Serologicals' Upstate Group Announces Five Finalists for the 2006 Young Cell Signaller Award; Winner to be chosen June 13, 2006 at the Third Annual Cell Signalling Symposium
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) today announced that five finalists from 83 entries have been chosen for its Upstate Group 2006 Young Cell Signaller Award. Entries were submitted as abstracts by Ph.D. students and first time post-doctorates competing to win $17,000 worth of support funding for their laboratory's reagents,...
Bellwether Report Issues Alert On Serologicals Corp.
M2 PRESSWIRE-25 April 2006-bellwetherreport.com: Bellwether Report Issues Alert On Serologicals Corp.C1994-2006 M2 COMMUNICATIONS LTD RDATE:25042006 The Bellwether Report Takes Notice Of Serologicals Corp. (Nasdaq:SERO) Serologicals is serious and logical about biology. The company supplies major health care companies with specialty biological...
Chemicon International and Australian Stem Cell Centre Announce Exclusive Agreement to Commercialize Stem Cell Products
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) and the Australian Stem Cell Centre ASCC announced today that they have signed an agreement whereby Chemicon International, Inc., Serologicals' wholly-owned subsidiary, has obtained exclusive rights to commercialize, market and distribute stem cell reagents developed at the ASCC to scientists all over the world....
Serologicals Corporation Schedules First Quarter Earnings Release and Conference Call
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that it will release its first quarter earnings on Wednesday, April 26, 2006 after the close of regular trading hours, and then host a conference call on Thursday, April 27, 2006 at 9:00 a.m. ET to review the results. The conference...
Serologicals Corporation Agrees to Acquire Cytomyx Ltd.; Expands Drug Discovery Screening Portfolio
ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today a definitive agreement to acquire Cytomyx Ltd., a wholly owned subsidiary of Cytomyx Holdings Plc (AIM: CYX). Based in Cambridge, U.K., Cytomyx Ltd. is a leading provider of ion channel cell lines and drug discovery services. With 23 distinct ion channel cell...
Chemicon International and Stem Cell Sciences Announce Launch of ESGRO Complete™ Product Line
ATLANTA -- New Grade of Serum and Feeder-Free Media for Mouse Embryonic Stem Cell Expansion Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Stem Cell Sciences plc (LSE:STEM, SCS) are launching the ESGRO CompleteTM product line for murine embryonic stem ES cell culture,...
Serologicals Corporation Reports Fourth Quarter and Full Year 2005 Results; Fourth Quarter Revenue up 26.0% and Pro Forma Net Income up 75.1%
ATLANTA -- Serologicals Corporation (NASDAQ:SERO) today announced financial results for the fourth quarter of our fiscal year ended January 1, 2006 (fiscal 2005). Revenues for the fourth quarter increased 26.0%, to $87.1 million, compared to $69.2 million in the same period last year, while revenues for fiscal 2005 increased 40.3%,...
Serologicals Corporation Schedules Fourth Quarter Earnings Release and Conference Call
ATLANTA -- Serologicals Corporation (NASDAQ:SERO) announced today that it will release its fourth quarter earnings on Wednesday, February 22, 2006 after the close of regular trading hours, and then host a conference call on Thursday, February 23, 2006 at 9:00 a.m. ET to review the results.
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Dwain Wilcox | |
| Jeffrey D. Linton | |
| Phil Theodore | Corporate Secretary |
| Wade Fetzer | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Desmond H. O'Connell | Chairman |
| Gerard M. Moufflet | Board of Directors |
| Harold W. Ingalls | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Serologicals Corporation | Current | |
| Accenture Ltd. | consultant | Former |
| State of Florida.Com | independent consultant | Former |
| Organization | Position | Status |
|---|---|---|
| Chemicon International Inc. | President, Chemicon | Current |
| Serologicals Corporation | Current |
Phil Theodore was named Senior Vice President and General Counsel of John H. Harland Company in 2006. He replaces John Walters who will retire in early 2007. He is responsible for all of Harland's legal and corporate governance activities. Theodore brings almost 30 years of legal experience to Harland, most recently as Vice President, General Counsel and Corporate Secretary for Serologicals Corporation prior to its acquisition by Millipore Corporation earlier this year. He joined Serologicals in 2004 after a 22-year career with King & Spalding LLP, where he specialized in mergers, acquisitions, corporate governance and corporate finance. Theodore received his bachelor's degree from the University of Tennessee and his law degree from the University of Cincinnati.
| Organization | Position | Status |
|---|---|---|
| Harland Financial Solutions, Inc. | Senior Vice President and General Counsel | Current |
| Serologicals Corporation | Corporate Secretary | Current |
| Millipore Corporation | Corporate Secretary | Current |
| John H. Harland Company | Senior Vice President and General Counsel | Former |
| Serologicals Corporation | Vice President, General Counsel | Former |
| King & Spalding LLP | Former | |
| University of Cincinnati | Law Degree | Former |
| The University of Tennessee | Bachelor's Degree | Former |
Desmond H. O Connell, Jr. became a director of the company in January 2007. He has been an independent management consultant and private investor since 1990. He was a Director of Serologicals Corporation from 1998 to 2006, serving also as Acting Chief Executive Officer for a year and subsequently as Chairman of the Board until Serologicals was sold in July 2006. Mr. O Connell has served as a Director of Abiomed, Inc. since 1995 and is currently a member of its Audit Committee and Governance and Nominating Committee. During 1991, he served briefly as Chairman of the Board and Chief Executive Officer of Osteotech, Inc. Mr. O Connell is a Trustee and Director of New Community Corporation in Newark, New Jersey. He holds an M.B.A. from Harvard University Graduate School of Business and is a graduate of the University of Notre Dame in Indiana.
| Organization | Position | Status |
|---|---|---|
| StemCells, Inc. | Independent Management Consultant and Private Investor | Current |
| Serologicals Corporation | Chairman | Current |
| ABIOMED, Inc. | Director | Current |
| Serologicals Corporation | Director | Current |
| Osteotech, Inc. | Chief Executive Officer | Former |
| The BOC Group plc | Group Managing Director | Former |
| StemCells, Inc. | Board of Directors | Former |
Gerard Moufflet is CEO and Founder of Acceleration International, a Boston-based Private Equity firm specializing in biotechnology, medical device, and healthcare services fields in both Europe and the US . From 1989 to 2001, Mr. Moufflet was a Managing Director at Advent International, one of the world's leading Private Equity Investment firms with funds under management totaling over $6 billion, where he headed the healthcare team and oversaw investments in Europe and in the United States . Mr. Moufflet had a seventeen-year career with healthcare giant Baxter International, where he led various European and African operations and eventually became Head of Worldwide Strategic Planning for the dialysis product line. When he became Corporate Vice President and Vice President of Baxter World Trade, Baxter had grown to $7 billion in sales. Mr. Moufflet currently serves on the board s of several publicly-held and privately-held companies. Mr. Moufflet is Chairman of the Board of Fellows of the Harvard Dental School of Medicine and the Chairman of the French Library and Cultural Center of Boston. Mr. Mouf flet received his undergraduate degree from Ecole des Hautes Etudes Commerciales in France and an MBA from the University of Pittsburgh . He is also a graduate of the Advanced Management Program at Harvard Business School.
| Organization | Position | Status |
|---|---|---|
| Plebys | Founder and CEO, Acceleration International | Current |
| American Dental Partners, Inc. | Chief Executive Officer, Acceleration International | Current |
| Acceleration International | Chief Executive Officer | Current |
| NGN Capital | CEO of Kika Medical International | Current |
| Kika Medical | President | Current |
| Acceleration International | Founder | Current |
| Medical Simulation Corporation | Team Member | Current |
| Curative Health Services, Inc. | Board Member | Current |
| Plebys | Board of Directors | Current |
| Serologicals Corporation | Board of Directors | Current |
| NGN Capital | Board of Directors | Current |
| American Dental Partners, Inc. | Board of Directors | Current |
| Kika Medical | Chairman and CEO | Former |
| Baxter International Inc. | President and Vice President | Former |
| Advent International Corporation | Managing Director | Former |
| University of Pittsburgh | Mba (1969) | Former |
| Fellows, Inc. | Chairman of the Board | Current |
| Organization | Position | Status |
|---|---|---|
| Cardiomems, Inc. | Chief Financial Officer | Current |
| Exi.Net | Vice President and Chief Financial Officer | Current |
| Serologicals Corporation | Board of Directors | Current |
| American Institute of Certified Public Accountants | Board of Directors | Current |
| Tikvah Therapeutics, Inc. | Board of Directors | Current |
| American Institute of Certified Public Accountants | Member | Current |
| LaRoche Industries Inc. | Chief Executive Officer | Former |
| LaRoche Industries Inc. | President | Former |
| Serologicals Corporation | Chief Financial Officer | Former |
| Cardiomems, Inc. | Vice President | Former |
| Serologicals Corporation | Vice President | Former |
| University of Wisconsin | B.B.A. Degree In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Rush Presbyterian - St. Luke's Medical Center | Director of the Executive Committee | Current |
| Sphere Communications, Inc. | Current | |
| Northern Star Broadcasting LLC | Director | Current |
| Serologicals Corporation | Director | Current |
| Medcor, Inc. | Director | Current |
| Northwestern University | President | Former |
| The Goldman Sachs Group, Inc. | Limited Partner | Former |
| The Goldman Sachs Group, Inc. | advisory director | Former |
| Corporate Governance | member | Former |
| Corporate Governance | Chairman | Former |
| Northwestern University | MBA | Former |
| University of Wisconsin | BS Degree | Former |
Industry Transcripts by Seeking Alpha
-
51jobs Q3 2009 Earnings Call Transcript
on Nov 23, 2009about JOBS
-
NetEase Q3 2009 Earnings Call Transcript
on Nov 18, 2009about NTES
-
Franklin Covey Co. F4Q09 (Qtr End 08/31/09) Earnings Call Transcript
on Nov 16, 2009about FC
-
Cellcom Israel Ltd. Q3 2009 Earnings Call Transcript
on Nov 16, 2009about CEL
-
URS Corporation Q3 2009 Earnings Call Transcript
on Nov 13, 2009about URS


